Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T02:28:45.374Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral Administration of Chemotherapeutic Agents Using Complexation Hydrogels

Published online by Cambridge University Press:  01 February 2011

James Blanchette ,
Kinam Park  and
Nicholas A Peppas
James Blanchette
Affiliation:
Department of Biomedical Engineering
Kinam Park
Affiliation:
Department of Biomedical Engineering School of Industrial and Physical Pharmacy
Nicholas A Peppas
Affiliation:
Department of Biomedical Engineering School of Chemical Engineering Purdue University West Lafayette, IN, 47907, USA.
Get access

Abstract

Carriers were synthesized to target delivery of a chemotherapeutic agent, bleomycin, to the upper small intestine in response to the pH shift when entering the upper small intestine from the stomach. Complexation hydrogels capable of pH-responsive swelling were used to form these carriers. Hydrogel nanospheres composed of methacrylic acid (MAA) and poly(ethylene glycol) (PEG) were loaded with bleomycin. Loading of bleomycin was performed by in situ polymerization and release of bleomycin from the nanospheres was measured by UV spectrophotometry. Results showed that bleomycin release from the nanospheres was responsive to the pH of the environment surrounding the nanospheres. In addition to pH-responsive release of bleomycin, the hydrogel nanospheres are also able to enhance the permeability of an in vitro model of the intestinal epithelium. Increasing the permeability of the intestinal epithelium could aid in transport of bleomycin from the lumen of the small intestine out into the bloodstream.

Type
Research Article
Information
MRS Online Proceedings Library (OPL) , Volume 724: Symposium N – Biological and Biomimetic Materials Properties to Function , 2002 , N10.4
Copyright
Copyright © Materials Research Society 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Sparreboom, A., Jonge, M.J.A. de and Verweij, J., Eur J Cancer 38, 18–22 (2002).Google Scholar
2. Gore, M., Oza, A., Rustin, G., Malfetano, J., Calvert, H., Clarke-Pearson, D., Carmichael, J., Ross, G., Beckman, R.A. and Fields, S.Z., Eur J Cancer 38, 57–63 (2001).Google Scholar
3. Pawel, J. von, Gatzemeier, U., Pujol, J.L., Moreau, L., Bildat, S., Ransom, M., Richardson, G., Steppert, C., Riviere, A., Camlett, I., Lane, S. and Ross, G., J Clin Oncol 19, 1743–9 (2001).Google Scholar
4. Hoff, P.M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Mauron, J., Walde, D., Weaver, C., Harrison, E., Burger, H.U., Osterwalder, B., Wong, A.O. and Wong, R., J Clin Oncol 19, 2282–92 (2001).Google Scholar
5. Umezawa, H., Maeda, K., Takeuchi, T. and Okami, Y., J Antibiot (Tokyo) Ser A 19, 200–9 (1966).Google Scholar